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Recent advances in stem cell biology have resulted in identifying new agents to differentiate stem cell-
derived-neural cells. Different stem cell types have been shown to differentiate into neural cells. It has
been shown that P19 line of embryonal carcinoma cells develops into neurons and astroglia after expo-
sure to some hormones such as dehydroepiandrosterone (DHEA). Steroid 5a-reductase is a key enzyme in
the conversion of several D4-3 keto steroids, such as testosterone into their respective 5a-reductase
derivatives. Finasteride is a 5a-reductase inhibitor that inhibits conversion of testosterone to the more
potent androgen dihydrotestosterone (DHT). Reduction in DHT and sustaining testosterone levels has
an important impact on differentiation and proliferation of embryonal carcinoma cells to neural cells.
We hypothesize that ﬁnasteride, a 5a-reductase inhibitor, will be differentiate embryonal carcinoma cell
to the neural cell and increase their proliferation due to the elevation levels of testosterone, a neuropro-
tective neurosteroid.
 2010 Published by Elsevier Ltd.Background
Culture of embryonal carcinoma (EC) cells revealed the poten-
tial application of these cells in developing assays of pharmacol-
ogy, toxicology and cell therapy in a large spectrum of diseases.
Protocols for controlled differentiation of EC cells ordinarily de-
pend on the application of growth and/or differentiation factors
in a deﬁned temporal order.
The aggregation of EC cells to embryoid bodies is used to induce
differentiation. The embryoid bodies represent multicellular struc-
tures which undergo spontaneous differentiation in derivatives of
germ layers [1]. Initial differentiation of embryoid bodies occurs
when the outer cells of the aggregate differentiate into endo-
derm-like cells that surround an undifferentiated core [1]. Embry-
onal carcinoma cells are derived from teratocarcinomas. Malignant
teratomas also contain populations of undifferentiated stem cells
that can grow as undifferentiated cell lines [2,3]. Examples of such
cells that have been applicable are the human Tera-2 EC cells [4],
mouse F9 EC cells [5] and P19 EC cells [6].
Early works showed that P19 EC cells are very suitable for iso-
lating clonal sub-lines. In addition, hormones like retinoic acid
(RA) and neurosteroids induce differentiation of EC cells, in mono-Elsevier Ltd.
acology Department, Kashan
3615550021 25.layer culture, without an aggregation phase [7,8]. It was shown
that relatively high concentrations of RA induce the formation of
neuronal and glial cells [9], while 0.5–1% DMSO leads to the forma-
tion of a wide variety of endodermal and mesodermal tissues [10].
Dehydroepiandrosterone (DHEA) is a neurosteroid that has been
shown to be a potential signaling molecule in neuronal differenti-
ation during development. DHEA can increase proliferation of hu-
man neural stem cells. DHEA has recently been shown to be
neuroprotective [11]. The adrenal cortex is the primary source of
circulating concentrations of DHEA [12], which is secreted in re-
sponse to adrenal corticotropin-releasing hormone [13]. DHEA act
as the precursor to the approximately 50% of androgens in adult
men and positively regulate elevation of testosterone [14]. DHEA
production and concentration declines signiﬁcantly and steadily
during aging [15]. Testosterone is an important determinant of
body composition in masculine. Its administration is associated
with hypertrophy of muscle ﬁbers and signiﬁcant increases inmyo-
nuclear, satellite and neural cell numbers [16]. Transdifferentiation
into neural stem cells and differentiating neurons was observed in
human stem cells after exposure to certain combinations of
steroids especially testosterone [17]. Testosterone enhances neuro-
genesis via increased cell survival through an androgen dependent
mechanism [18].
Recently, ﬁnasteride was described as a potential clinical
candidate for the treatment of androgen-dependent disorders.
Finasteride is an inhibitor of 5a-reductase. Steroid 5a-reductase
12 A. Shoae-Hassani et al. /Medical Hypotheses 76 (2011) 11–13is a NADPH-dependent enzyme which converts testosterone to
the more potent androgen, 5a-dihydrotestosterone (DHT), pro-
gesterone to dihydroprogesterone and deoxycorticosterone to
dihydrodeoxycorticosterone, steroids modulating the action of
c-aminobutyric acid on GABA receptors [19]. In an extensive
investigation of the effects of androgens on the proliferation,
differentiation, and function of stem cells, it was clear that
DHT inhibits the differentiation of stem cells. The ﬁnal effect
is a reduced number of fully differentiated cells [20]. Like DHEA,
ﬁnasteride increase testosterone levels and decrease other
androgen levels [21].
Understanding the consequence actions of DHEA, DHT and ﬁn-
asteride inspired us to propose that ﬁnasteride, the 5a-reductase
inhibitor, will be differentiate embryonal carcinoma cell to the
neural cell and increase proliferation of neural cells due to eleva-
tion of testosterone, a neuroprotective neurosteroid.
Hypothesis
Testosterone levels have an important impact on differentiation
and proliferation of embryonal stem cells to neural cells. The
hypothesis we propose here is that ﬁnasteride, a 5a-reductase
inhibitor, that could change the balance between testosterone
and DHT will be differentiate embryonal carcinoma cell to neural
cell and increase proliferation of neural cells. The hypothesis is
due to elevation of testosterone and lessens in DHT levels. DHT, a
non-aromatizable androgen, can decrease proliferation and differ-
entiation of EC cells and its existence is contrarily to ﬁnasteride
role. This idea would be important and has implication for future
use.
Evaluation of hypothesis
Investigations of androgens effects on differentiation of stem
cells revealed that DHT inhibits the differentiation of stem cells.
Adipocytes differentiated from stem cells in the presence of DHT
are smaller and accumulate fewer lipids [20]. Testosterone and
DHT regulate the differentiation of pluripotent cells of mesenchy-
mal origin; these androgens stimulate myogenic differentiation
while inhibiting adipogenic differentiation [22]. Androgens regu-
late body composition by stimulating the commitment of pluripo-
tent cells that are resident within the skeletal muscle and
elsewhere into the myogenic lineage [22].
Finasteride blocks the actions of DHT that mainly has actions on
the prostate and hair loss. Therefore, testosterone replacement can
be safely prescribed alongside ﬁnasteride in patients with low tes-
tosterone [23]. The presence of 100 nM/L ﬁnasteride during the
ischemic insult results in substantial protection. In some cases sur-
viving rate of neurons is quantiﬁed by counting distinct function-
ally active neurons before and after insult [19].
Discussion
Androgens inhibit bodies fat mass; thus, their deﬁciency is asso-
ciated with higher fat mass [24], and testosterone supplementation
lessens whole body and inter-muscular fat mass [25,26]. DePergola
has reported that testosterone inhibits differentiation of precursor
cells, suppresses lipid uptake and lipoprotein lipase activity, and
up-regulates the number of beta-adrenergic receptors [27].
Pregnenolone, a steroid precursor of testosterone, had no signif-
icant effect on the differentiation of stem cells, indicating that
these effects are speciﬁc to androgenic steroids. Steroids affect
neuronal operation through binding to cognate intracellular recep-
tors which may act as transcription factors in regulation of gene
expression [28].Neuroactive steroids modulate ligand-gated ion channels via
non-genomic mechanisms. Classical steroid hormones such as tes-
tosterone and progesterone are neuroactive steroids because they
may act as functional antagonists at the 5-hydroxytryptamine
receptor, a ligand-gated ion channel or distinct glutamate recep-
tors. Although a binding’s site for steroids at GABAA receptors is
still a subject for further discussions, there is an evidence that ste-
roids interact allosterically with ligand-gated ion channels at the
receptor membrane interface [28].
Animal studies showed that testosterone is converted rapidly
into GABAergic neuroactive steroids in vivo. It reduces locomotor
activity in a dose-dependent fashion in Wistar rats. Both the geno-
mic and non-genomic effects of steroids in the brain may contrib-
ute to pathophysiological disorders. Neuroactive steroids affect
embryonal carcinoma cells and may represent a new treatment
strategy for neurological disorders [29].
This discussion suggests a promising strategy for promoting
neurogenesis by ﬁnasteride in the aged brain and potentially for
restoration of neuronal populations in brains recovering from neu-
rodegenerative disease or injury.Conclusion
In summary according to the theory mentioned above, we
would use the ﬁnasteride to induce development of neurons in cul-
tures of P19 cells. Finasteride could provide a suitable inducer for
differentiation of stem cell-derived-neural cells, including neuro-
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